Page last updated: 2024-09-04

mdl 100240 and Disease Models, Animal

mdl 100240 has been researched along with Disease Models, Animal in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Agabiti-Rosei, E; Bova, S; Cavallin, M; Mazzocchi, G; Nussdorfer, GG; Pessina, AC; Rizzoni, D; Rossi, GP	1
Agabiti-Rosei, E; Bianchi, R; De Ciuceis, C; Nussdorfer, GG; Paiardi, S; Porteri, E; Rezzani, R; Rizzoni, D; Rodella, L; Rossi, GP; Sleiman, I; Sticchi, D	1

Other Studies

2 other study(ies) available for mdl 100240 and Disease Models, Animal

Article	Year
Dual ACE and NEP inhibitor MDL-100,240 prevents and regresses severe angiotensin II-dependent hypertension partially through bradykinin type 2 receptor. Journal of hypertension, 2002, Volume: 20, Issue:7 Topics: Adrenomedullin; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Antihypertensive Agents; Benzazepines; Biomarkers; Blood Pressure; Body Weight; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Heart; Hypertension; Male; Models, Cardiovascular; Neprilysin; Organ Size; Peptides; Pyridines; Ramipril; Rats; Rats, Sprague-Dawley; Receptor, Bradykinin B2; Receptors, Bradykinin; Severity of Illness Index; Systole; Treatment Outcome; Vasoconstrictor Agents	2002
Bradykinin and matrix metalloproteinases are involved the structural alterations of rat small resistance arteries with inhibition of ACE and NEP. Journal of hypertension, 2004, Volume: 22, Issue:4 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Benzazepines; Bradykinin; Bradykinin Receptor Antagonists; Disease Models, Animal; Drug Interactions; Hypertension; Immunohistochemistry; Male; Matrix Metalloproteinases; Mesenteric Arteries; Myography; Neprilysin; Pyridines; Ramipril; Rats; Rats, Sprague-Dawley; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Vascular Resistance; Vasoconstriction	2004

Article

Year

Dual ACE and NEP inhibitor MDL-100,240 prevents and regresses severe angiotensin II-dependent hypertension partially through bradykinin type 2 receptor.

Journal of hypertension, 2002, Volume: 20, Issue:7

Topics: Adrenomedullin; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Antihypertensive Agents; Benzazepines; Biomarkers; Blood Pressure; Body Weight; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Heart; Hypertension; Male; Models, Cardiovascular; Neprilysin; Organ Size; Peptides; Pyridines; Ramipril; Rats; Rats, Sprague-Dawley; Receptor, Bradykinin B2; Receptors, Bradykinin; Severity of Illness Index; Systole; Treatment Outcome; Vasoconstrictor Agents

2002

Bradykinin and matrix metalloproteinases are involved the structural alterations of rat small resistance arteries with inhibition of ACE and NEP.

Journal of hypertension, 2004, Volume: 22, Issue:4

Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Benzazepines; Bradykinin; Bradykinin Receptor Antagonists; Disease Models, Animal; Drug Interactions; Hypertension; Immunohistochemistry; Male; Matrix Metalloproteinases; Mesenteric Arteries; Myography; Neprilysin; Pyridines; Ramipril; Rats; Rats, Sprague-Dawley; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Vascular Resistance; Vasoconstriction

2004